MedTrace Logo

Clinical Study of SM3321 With Solid Tumors

NCT06087770 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-12-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Safety and Tolerability of SM3321 in patients with locally advanced or metastatic solid tumors

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

SM3321

Intravenous infusion, once a week, 28 days for a dosing cycle

Sponsors & Collaborators

  • Beijing StarMab Biomed Technology Ltd

    lead INDUSTRY

Principal Investigators

  • Qi Li, Dr. · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-07
Primary Completion
2025-08-19
Completion
2025-10-14
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06087770 on ClinicalTrials.gov